Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Spondyloarthritis family · A closer look at PsA

PsA biomarkers: what tests can tell us—and what they cannot

A biomarker becomes useful when it answers a defined question. Distinguish a measure of inflammation from a test that diagnoses disease, predicts its course or helps choose between treatments.

Olga Goodman, MD · Sources checked 27 September 2026

Chapter 19 of 21

The essentials

There is no single blood test that confirms or excludes PsA. Personalised care already uses clinical findings and individual circumstances; reliable molecular selection of the best drug remains an active research goal.

First ask what the marker is for

A biomarker is a measurable biological characteristic. Its purpose matters: showing current inflammation, estimating future risk, predicting a treatment benefit and checking drug safety are different tasks. A marker validated for one task is not automatically useful for another. 7

What is useful in everyday care?

Results are interpreted with symptoms, examination, previous measurements and treatment exposure. An abnormal value needs an explanation; a normal value needs context. 2

What is useful in everyday care?
MeasurementUse and boundary
CRP and ESRSupport assessment of inflammation and trends. Normal CRP can coexist with active PsA; a raised value is not specific to PsA. 8
RF and anti-CCP antibodiesMay help evaluate rheumatoid arthritis and alternative explanations. They do not independently prove or rule out PsA. 2
HLA-B27May support interpretation of selected axial presentations. It is neither a universal PsA screening test nor a personal forecast. 21
Ultrasound or MRICan assess particular tissues when clinically useful. Findings depend on site, technique and context; a sensitive scan is not automatically a specific diagnosis. 4
Blood count, liver and kidney testsOften monitor treatment safety. A satisfactory safety result does not by itself mean the arthritis is controlled. 2

Personalisation already has a practical meaning

Choosing care around the affected domains, previous response, other illnesses, pregnancy plans and personal priorities is personalised medicine. It does not require an unvalidated molecular panel. 3

A proposed test should answer a decision: would this result change the drug, timing, dose or follow-up? If both possible results lead to the same plan, the test may add little at that moment.

What researchers are measuring

Proteomics studies many proteins; transcriptomics studies RNA activity; genetic studies examine inherited variation. Imaging and tissue samples may add information that is absent from blood. Combining measurements is promising, but also creates more opportunities to find chance patterns.

Exploratory PsA trial analyses have linked molecular signals with disease activity or treatment response. A 2024 deucravacitinib analysis is one example. Association within a trial is a starting point for validation, not a ready-made test for selecting a drug in routine practice. 9

What would make a test convincing?

It should be reproducible, use a clear threshold and predict well in an independent group similar to the intended patients. Researchers must then show that decisions guided by the test improve outcomes compared with usual care. A commercial report or high accuracy in the development sample does not settle these questions.

The 2026 Integrate-PsA publication is a protocol for developing a predictive panel. Its value is the planned question and design; it does not report an already validated clinical selection tool. 11

Go deeper

Prognostic is different from predictive

A prognostic marker estimates an outcome, such as persistent activity, irrespective of a particular treatment. A predictive marker helps identify a difference in treatment benefit. A marker falling after therapy may simply show a biological response. These distinctions are part of the FDA–NIH BEST framework. 7

Imagine that people with marker X improve on drug A. To choose A over B using X, we need evidence that X helps distinguish their relative benefit—not merely that it identifies people likely to improve on either. This is a teaching example, not a PsA test recommendation.

Questions for your visit

  1. What precise decision would this test change?
  2. Is its purpose diagnosis, monitoring, safety or treatment selection?
  3. Has the result been validated in independent PsA patients like me?

When to seek urgent help

A painful red eye, light sensitivity or a sudden change in vision needs urgent assessment. A newly hot, swollen joint, especially with fever or feeling unwell, also needs prompt assessment.

Sources & evidence notes

Sources checked 27 September 2026

Dates identify the cited publications. Protocols, exploratory analyses and clinical results answer different questions. This is a selected reading route, not a complete evidence review.

  1. NIAMS. Psoriatic arthritis: diagnosis, treatment and steps to take.
  2. EULAR recommendations for PsA: 2023 update (published 2024).
  3. Zabotti et al. EULAR points to consider: progression from psoriasis to PsA (2023).
  4. FDA. About biomarkers and qualification: BEST categories.
  5. Gialouri et al. Normal C-reactive protein in active PsA (2022).
  6. FitzGerald et al. Deucravacitinib phase 2: exploratory biomarker analysis (2024).
  7. Shekhar et al. Integrate-PsA: prospective observational study protocol (2026).
  8. REGISPONSER: axial PsA phenotype and HLA-B27 (2022).

Educational information for patients and caregivers. This personal publication is not the clinic portal and does not provide individual diagnosis or treatment. Discuss medication changes with your own care team.

© 2026 Olga Goodman, MD · A RheumaView publication. Copying without attribution prohibited.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Medical researchPsoriasisPsoriatic arthritisSpondyloarthritis